Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls

Figures & data

Figure 1 Flow chart of study selection.

Abbreviations: CNKI, Chinese National Knowledge Infrastructure; MDM2, mouse double minute 2 homolog.

Table 1 Characteristics of the studies included in the meta-analysis

First author	Year	Country	Ethnicity	Study design	Genotyping method	Total sample size (Case/control)
Boersma et al^Citation16	2006	USA	Caucasian African-American	CC	PCR	290/314
Campbell et al^Citation17	2006	UK	Caucasian	CC	PCR	351/258
Millikan et al^Citation18	2006	USA	Caucasian African-American	CC	PCR-RFLP	2,037/1,813
Petenkaya et al^Citation19	2006	Turkey	Mixed	CC	PCR-RFLP	223/149
Ma et al^Citation21	2006	People’s Republic of China	Asian	CC	PCR	366/605
Wilkening et al^Citation20	2006	Germany	Caucasian	CC	qPCR	549/1,065
Wasielewski et al^Citation22	2007	The Netherlands	Caucasian	CC	PCR	343/126
Cox et al^Citation23	2007	America	Mixed	CC	PCR-RFLP	1,519/2,271
Lum et al^Citation24	2008	Singapore	Asian	CC	PCR	402/128
Singh et al^Citation25	2008	India	Asian	CC	qPCR	104/105
Paulin et al^Citation26	2008	England	Caucasian	CC	qPCR	299/275
Krekac et al^Citation27	2008	Czech Republic	Caucasian	CC	PCR-RFLP	158/149
Yarden et al^Citation28	2008	Israel	Caucasian	CC	qPCR	187/138
Lang et al^Citation29	2009	Sweden	Caucasian	CC	PCR-RFLP	123/146
Sun et al^Citation30	2009	People’s Republic of China	Asian	CC	PCR-RFLP	124/97
Koh et al^Citation31	2011	Singapore	Asian	CC	qPCR	385/614
Leu et al^Citation32	2011	People’s Republic of China	Asian	CC	PCR	255/324
Knappskog et al^Citation33	2011	WEC, Finland	Caucasian	CC	PCR-RFLP/Taqman	1,973/2,518
Alshatwi et al^Citation34	2012	Saudi Arabia	Asian	CC	PCR	100/100

Abbreviations: CC, case–control; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; WEC, Western European countries including the UK, the Netherlands, and Norway; qPCR, quantitative PCR.

Figure 2 Forest plots of the MDM2 rs 2279744 polymorphism and breast cancer risk in the overall population (TG vs TT).

Notes: The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
Abbreviations: CI, confidence interval; OR, odds ratio; df, degrees of freedom; M-H, Mantel-Haenszel; MDM2, mouse double minute 2 homolog.

Table 2 Meta-analysis of the association between the MDM2 rs 2279744 polymorphism and breast cancer risk

Comparisons	OR	95% CI	P-value	Heterogeneity		Effects model
				I^2	P-value
G vs T	1.03	0.99–1.08	0.11	36%	0.06	Random
Asian	1.12	1.02–1.23	0.02	54%	0.04	Random
Eastern Asian	1.07	0.97–1.19	0.17	65%	0.02	Random
Caucasian	1.03	0.97–1.09	0.30	0%	0.60	Fixed
African	1.15	0.94–1.42	0.17	37%	0.21	Fixed
GG vs TT	1.09	1.00–1.19	0.04	35%	0.07	Random
Asian	1.29	1.06–1.56	0.01	55%	0.04	Random
Eastern Asian	1.25	1.01–1.54	0.04	55%	0.06	Random
Caucasian	1.10	0.98–1.23	0.11	0%	0.59	Fixed
African	0.75	0.39–1.47	0.40	0%	0.57	Fixed
TG vs TT	1.10	1.04–1.17	0.001	18%	0.23	Fixed
Asian	1.36	1.15–1.60	0.0004	0%	0.45	Fixed
Eastern Asian	1.37	1.15–1.64	0.0006	20%	0.29	Fixed
Caucasian	1.09	1.00–1.18	0.04	8%	0.37	Fixed
African	1.31	1.03–1.66	0.03	60%	0.11	Fixed
TG+GG vs TT	1.06	1.00–1.12	0.05	50%	0.007	Random
Asian	1.21	1.03–1.41	0.02	49%	0.07	Random
Eastern Asian	1.19	1.00–1.41	0.05	58%	0.05	Random
Caucasian	1.03	0.95–1.11	0.52	42%	0.08	Random
African	1.24	0.99–1.56	0.07	53%	0.14	Fixed
GG vs TT+TG	1.02	0.95–1.11	0.55	0%	0.50	Fixed
Asian	1.04	0.89–1.21	0.63	38%	0.14	Fixed
Eastern Asian	1.00	0.85–1.18	0.99	16%	0.31	Fixed
Caucasian	1.04	0.93–1.16	0.47	0%	0.48	Fixed
African	0.72	0.37–1.40	0.33	0%	0.52	Fixed

Abbreviations: CI, confidence interval; OR, odds ratio; vs, versus; G, Guanine; T, Thymine; GG vs TT, homozygous genetic model; TG vs TT, allele contrast genetic model; TG+GG vs TT, dominant model; GG vs TT+TG, recessive model; MDM2, mouse double minute 2 homolog.

Figure 3 Forest plots showing the relationship between the MDM2 rs 2279744 polymorphism and breast cancer risk in the Asian subgroup; (A) G vs T; (B) GG vs TT; (C) TG vs TT; (D) TG+GG vs TT.

Abbreviations: CI, confidence interval; OR, odds ratio; df, degrees of freedom; M-H, Mantel-Haenszel; G, Guanine; T, Thymine; GG vs TT, homozygous genetic model; TG vs TT, allele contrast genetic model; TG+GG vs TT, dominant model; GG vs TT+TG, recessive model; MDM2, mouse double minute 2 homolog.

Figure 4 Forest plot showing the relationship between the MDM2 rs 2279744 polymorphism and breast cancer risk in the African subgroup (TG vs TT).

Abbreviations: CI, confidence interval; OR, odds ratio; df, degrees of freedom; M-H, Mantel-Haenszel; vs, versus; MDM2, mouse double minute 2 homolog; TG vs TT, allele contrast genetic model.

Figure 5 Funnel plot assessing evidence of publication bias from 19 studies (TG vs TT).

Abbreviations: SE, standard error; OR, odds ratio; TG vs TT, allele contrast genetic model.

BoersmaBJHoweTMGoodmanJEAssociation of breast cancer outcome with status of p53 and MDM2 SNP309J Natl Cancer Inst20069891191916818855

 PubMedGoogle Scholar

CampbellIGEcclesDMChoongDYNo association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancerCancer Lett200624019519716239061

 PubMed Web of Science ®Google Scholar

MillikanRCHeardKWinkelSNo association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or WhitesCancer Epidemiol Biomarkers Prev20061517517716434608

 PubMed Web of Science ®Google Scholar

PetenkayaABozkurtBAkilli-OzturkOKayaHSGur-DedeogluBYulugIGLack of association between the MDM2-309 polymorphism and breast cancer riskAnticancer Res2006264975497717214373

 PubMed Web of Science ®Google Scholar

MaHHuZZhaiXPolymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese populationCancer Lett200624026126716288830

 PubMed Web of Science ®Google Scholar

WilkeningSBermejoJLBurwinkelBThe single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancerCancer Res200666264664816423991

 PubMed Web of Science ®Google Scholar

WasielewskiMNagelJHBrekelmansCMDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signalingBreast Cancer Res Treat200710415315717080308

 PubMed Web of Science ®Google Scholar

CoxDGDeerDGuoQThe p53 Arg 72 Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studiesCancer Causes Control200718662162517387621

 PubMed Web of Science ®Google Scholar

LumSSChuaHWLiHMDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese populationCarcinogenesis200829475476118281248

 PubMed Web of Science ®Google Scholar

SinghVRastogiNMathurNSinghKSinghMPAssociation of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian womenAnn Epidemiol2008181485717719241

 PubMed Web of Science ®Google Scholar

PaulinFEO’NeillMMcGregorGMDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphismBMC Cancer2008828118828900

 PubMed Web of Science ®Google Scholar

KrekacDBrozkovaKKnoflickovaDMDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer riskOncology2008741–2848718547962

 PubMed Web of Science ®Google Scholar

YardenRIFriedmanEMetsuyanimSOlenderTBen-AsherEPapaMZMDM2 SNP309 accelerates breast and ovarian carci-nogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descentBreast Cancer Res Treat200811149750418026875

 PubMed Web of Science ®Google Scholar

LangAPalmebäck WegmanPWingrenSThe significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancerOncol Rep200922357557919639206

 PubMed Web of Science ®Google Scholar

SunYFLeuJDChenSMLinIFLeeYJResults based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancerBMC Cancer200991319144119

 PubMed Web of Science ®Google Scholar

KohWPVan Den BergDJinAWangRYuanJMYuMCCombined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in SingaporeBreast Cancer Res Treat201113031011101921833626

 PubMed Web of Science ®Google Scholar

LeuJDWangCYTsaiHYLinIFChenRCLeeYJInvolvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancerOncol Rep20112561755176321479369

 PubMed Web of Science ®Google Scholar

KnappskogSBjørnslettMMyklebustLMThe MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in CaucasiansCancer Cell201119227328221316605

 PubMed Web of Science ®Google Scholar

AlshatwiAAHasanTNShafiGAlsaifMAAl-HazzaniAAAlsaifAAA single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab populationFundam Clin Pharmacol201226343844321477265

 PubMed Web of Science ®Google Scholar